12-17岁青少年接种mRNA COVID-19疫苗后心肌心包炎的发生率:一项荟萃分析
该荟萃分析纳入15项观察性研究,汇总12-17岁青少年接种mRNA COVID-19疫苗后心肌心包炎的发生率。结果显示,接种BNT162b2和mRNA-1273后心肌心包炎总体发生率为每百万剂43.5例(95%CI 30.8-61.6),仅接种BNT162b2为41.8例(29.4-59.4);男性高于女性,第二剂高于第一剂。发生率极低,未高于天花疫苗和非COVID-19疫苗后的参考发生率,且显著低于COVID-19感染后的发生率。
要点
- 12-17岁青少年接种mRNA COVID-19疫苗后心肌心包炎发生率极低,为每百万剂43.5例。
- 男性发生率(66.0例/百万剂)高于女性(10.1例/百万剂),第二剂(60.4例)高于第一剂(16.6例)。
- 发生率未高于天花疫苗和非COVID-19疫苗后,且显著低于COVID-19感染后。
核心结论
- 12-17岁青少年接种mRNA COVID-19疫苗后心肌心包炎发生率极低,未高于其他重要参考发生率,为政策制定者和犹豫接种的家长权衡风险与获益提供依据。
研究设计与样本
- 荟萃分析,检索4个电子数据库至2023年2月6日,纳入报告12-17岁青少年接种mRNA COVID-19疫苗后发生心肌心包炎的观察性研究,共纳入15项研究。
主要发现
- 接种BNT162b2和mRNA-1273后心肌心包炎汇总发生率为每百万剂43.5例(95%CI 30.8-61.6;39 628 242剂;14项研究)。
- 仅接种BNT162b2后发生率为每百万剂41.8例(95%CI 29.4-59.4;38 756 553剂;13项研究)。
- 男性发生率为每百万剂66.0例(95%CI 40.5-107.7),女性为10.1例(95%CI 6.0-17.0)。
- 第二剂发生率为每百万剂60.4例(95%CI 37.6-96.9),第一剂为16.6例(95%CI 8.7-31.9)。
- 按年龄、心肌心包炎类型、国家和世界卫生组织区域分组,发生率无显著差异。
关键数值与推荐
- 本研究中汇总的心肌心包炎发生率均未高于天花疫苗和非COVID-19疫苗接种后的发生率。
- 所有汇总发生率均显著低于12-17岁青少年COVID-19感染后的发生率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence of myopericarditis after mRNA COVID-19 vaccination among adolescents aged 12-17 years remains unknown. Therefore, we conducted a study to pool the incidence of myopericarditis following COVID-19 vaccination in this age group. METHODS: We did a meta-analysis by searching 4 electronic databases until February 6, 2023. The following main keywords were used: "COVID-19", "vaccines", "myocarditis", "pericarditis", and "myopericarditis". Observational studies reporting on adolescents aged 12-17 years who had myopericarditis in temporal relation to receiving mRNA COVID-19 vaccines were included. The pooled incidence of myopericarditis and 95 % confidence interval (CI) were calculated using a single-group meta-analysis. RESULTS: Fifteen studies were included. The pooled incidences of myopericarditis after mRNA COVID-19 vaccination among adolescents aged 12-17 years were 43.5 (95 % CI, 30.8-61.6) cases per million vaccine doses for both BNT162b2 and mRNA-1273 (39 628 242 doses; 14 studies), and 41.8 (29.4-59.4) cases for BNT162b2 alone (38 756 553 doses; 13 studies). Myopericarditis was more common among males (66.0 [40.5-107.7] cases) than females (10.1 [6.0-17.0] cases) and among those receiving the second dose (60.4 [37.6-96.9] cases) than those receiving the first dose (16.6 [8.7-31.9] cases). The incidences of myopericarditis did not differ significantly when grouped by age, type of myopericarditis, country, and World Health Organization region. None of the incidences of myopericarditis pooled in the current study were higher than those after smallpox vaccinations and non-COVID-19 vaccinations, and all of them were significantly lower than those in adolescents aged 12-17 years after COVID-19 infection. CONCLUSIONS: The incidences of myopericarditis after mRNA COVID-19 vaccination among adolescents aged 12-17 years were very rare; they were not higher than other important reference incidences. These findings provide an important context for health policy makers and parents with vaccination hesitancy to weight the risks and benefits of mRNA COVID-19 vaccination among adolescents aged 12-17 years.
引用
- Guo BQ, Li HB, Yang LQ, et al. Incidence of myopericarditis after mRNA COVID-19 vaccination: A meta-analysis with focus on adolescents aged 12-17 years. Vaccine. 2023. PMID: 37246067. doi:10.1016/j.vaccine.2023.05.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。